Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer

Androgen Receptor Function and Androgen Receptor–Targeted Therapies in Breast Cancer

(2017) Miho Kono et al.   JAMA Oncology

PFTK1 regulates cell proliferation, migration and invasion in epithelial ovarian cancer

(2016) Weiwei Zhang et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer

(2016) R Mimoto et al.   ONCOGENE

Downregulated DYRK2 expression is associated with poor prognosis and Oxaliplatin resistance in hepatocellular carcinoma

(2016) Xiubing Zhang et al.   PATHOLOGY RESEARCH AND PRACTICE

Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer

(2016) Haiyan Yan et al.   PLoS One

Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma

(2015) Yuchan Wang et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Upregulated PFTK1 promotes tumor cell proliferation, migration, and invasion in breast cancer

(2015) Xiaoling Gu et al.   MEDICAL ONCOLOGY

Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis

(2015) Xing Guo et al.   NATURE CELL BIOLOGY

PFTK1 Promotes Gastric Cancer Progression by Regulating Proliferation, Migration and Invasion

(2015) Lei Yang et al.   PLoS One

DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma

(2015) Noriko Yamaguchi et al.   TUMOR BIOLOGY

Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy

(2015) Shunichiro Nomura et al.   BMC Urology

Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer

(2014) Yasuko Enomoto et al.   TUMOR BIOLOGY

DYRK2 controls the epithelial–mesenchymal transition in breast cancer by degrading Snail

(2013) Rei Mimoto et al.   CANCER LETTERS

Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma

(2012) H Miyagaki et al.   BRITISH JOURNAL OF CANCER

DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells

(2012) Naoe Taira et al.   JOURNAL OF CLINICAL INVESTIGATION

Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis

(2011) Mohammad H Forouzanfar et al.   LANCET

Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study

(2011) Laura C Collins et al.   MODERN PATHOLOGY

The MAPPER2 Database: a multi-genome catalog of putative transcription factor binding sites

(2011) A. Riva   NUCLEIC ACIDS RESEARCH

A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility

(2011) W K C Leung et al.   ONCOGENE

Expression of androgen receptors in primary breast cancer

(2009) S. Park et al.   ANNALS OF ONCOLOGY

The cell death machinery governed by the p53 tumor suppressor in response to DNA damage

(2009) Kiyotsugu Yoshida et al.   CANCER SCIENCE

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target

(2009) Yu Chen et al.   LANCET ONCOLOGY

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE